Top Page
Perspective Therapeutics
(CATX)
Perspective Therapeutics (CATX) vs. SPDR S&P 500 ETF (SPY)
Perspective Therapeutics Business Overview & Revenue Model
Perspective Therapeutics Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.43M | 7.10M | 10.79M |
| Gross Profit | 0.00 | 0.00 | 1.43M | 1.63M | 4.62M |
| EBITDA | 9.14M | 10.46M | -39.96M | -14.84M | -7.39M |
| Net Income | -103.12M | -79.28M | -46.51M | -14.67M | -7.15M |
Balance Sheet | |||||
| Total Assets | 266.97M | 341.10M | 97.89M | 58.09M | 67.25M |
| Cash, Cash Equivalents and Short-Term Investments | 144.74M | 226.92M | 9.24M | 43.76M | 60.35M |
| Total Debt | 1.63M | 4.06M | 2.55M | 0.00 | 652.00K |
| Total Liabilities | 59.94M | 50.43M | 22.71M | 3.45M | 2.86M |
| Stockholders Equity | 207.03M | 290.67M | 75.18M | 54.64M | 64.39M |
Cash Flow | |||||
| Free Cash Flow | -95.23M | -72.71M | -37.98M | -12.47M | -7.98M |
| Operating Cash Flow | -82.48M | -18.29M | -36.91M | -12.17M | -7.71M |
| Investing Cash Flow | 41.23M | -218.93M | 24.37M | -57.68M | -284.00K |
| Financing Cash Flow | 10.30M | 289.38M | 785.00K | 56.00K | 56.00K |
Perspective Therapeutics Technical Analysis
Perspective Therapeutics Risk Analysis
Perspective Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $336.23M | 19.35 | 10.87% | ― | 18.90% | 29.22% | |
76 Outperform | $192.65M | 21.81 | 20.28% | ― | 16.05% | 29.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $507.00M | -1.97 | -41.27% | ― | ― | ― | |
48 Neutral | $240.93M | -6.74 | 137.18% | ― | 49.52% | 19.34% | |
47 Neutral | $153.67M | -4.35 | -32.46% | ― | 15.19% | -3.32% | |
46 Neutral | $200.90M | -2.53 | -29.28% | ― | -2.69% | -149.18% |
Perspective Therapeutics Corporate Events
On March 16, 2026, Perspective Therapeutics reported full-year 2025 results and recent business highlights, underscoring progress across all three clinical-stage radiopharmaceutical programs and strengthening its financial position. Updated data for lead asset VMT-α-NET in neuroendocrine tumors showed favorable tolerability, absence of dose-limiting toxicities, durable disease control and deepening tumor responses, with Cohort 2 and Cohort 3 follow-up expected to support regulatory discussions and broader conference presentations in 2026.
The company also advanced VMT01 in heavily pre-treated melanoma at a 3.0 mCi dose, both as monotherapy and in combination with nivolumab, and expanded early clinical work on FAP-α–targeting PSV359, while preparing additional preclinical constructs for potential first-in-human imaging. Perspective ended 2025 with approximately $145 million in cash, cash equivalents and short-term investments and subsequently raised about $164 million in an equity offering, which it expects will fund planned clinical milestones and operational investments into late 2027, supporting continued pipeline and manufacturing expansion.
The most recent analyst rating on (CATX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
On February 2, 2026, Perspective Therapeutics, Inc. entered into an underwriting agreement for a previously announced underwritten offering of 39,576,088 common shares and pre-funded warrants to purchase 6,598,046 shares, priced at $3.79 per share and $3.789 per pre-funded warrant, respectively; the transaction, led by Piper Sandler and UBS Securities, closed on February 3, 2026 and generated approximately $175 million in gross proceeds. The company plans to deploy the net proceeds to advance clinical development of its radiopharmaceutical pipeline, expand and upgrade its manufacturing infrastructure, fund working capital and other general corporate needs, and potentially pursue acquisitions or licensing of complementary assets, moves that are expected to bolster its operational capacity and financial flexibility as it seeks to strengthen its position in the oncology theranostics market.
The most recent analyst rating on (CATX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
On February 2, 2026, Perspective Therapeutics posted an investor presentation outlining progress across its pipeline of 212Pb-based radiopharmaceutical therapies and its broader strategy in oncology. The company highlighted ongoing Phase 1/2a clinical trials for three wholly owned candidates: VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-α in advanced solid tumors, noting compelling anti-tumor activity, durable disease control, and favorable tolerability profiles to date. The presentation emphasized the potential first-in-class positioning of these agents, the optimization of targeted delivery through imaging and proprietary chelation technology, and the company’s secured clinical supply and scaling manufacturing infrastructure, with Phase 1/2 data expected across all three clinical programs in 2026—developments that underscore Perspective’s bid to strengthen its competitive position in the growing radiopharmaceutical market and its prospects for future registration-directed studies.
The most recent analyst rating on (CATX) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
On January 14, 2026, Perspective Therapeutics updated its corporate presentation to highlight progress on its 212Pb-based radioligand platform and expanding oncology pipeline. The company detailed three ongoing Phase 1/2a clinical programs—VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 for FAP-α–expressing solid tumors—all of which have shown early signals of anti-tumor activity and manageable safety profiles. It also emphasized its secured clinical supply, commercial-scale manufacturing build-out, and strong IP coverage, positioning the company to potentially advance registration-enabling studies and to compete more aggressively in the growing solid tumor radiopharmaceutical market, with additional Phase 1/2 data from all three programs expected in 2026.
The most recent analyst rating on (CATX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
On January 12, 2026, Perspective Therapeutics announced business updates and strategic priorities for the next 12–18 months, highlighting steady clinical progress across its pipeline and moves to scale manufacturing ahead of broader data readouts and regulatory engagement. Updated interim data from its lead VMT-α-NET program in neuroendocrine tumors, presented at ASCO-GI 2026, showed continued strong patient recruitment, a favorable safety profile with no dose-limiting toxicities or treatment-related serious adverse events among 56 treated patients, and signs of durable disease control and deepening tumor responses, positioning the program for more extensive conference presentations and discussions with regulators in 2026. The company also reported ongoing dose-finding work in its VMT01 melanoma program, including patients treated both as monotherapy and in combination with nivolumab at the 3.0 mCi dose, as well as early clinical activity in the PSV359 program targeting FAP-expressing solid tumors, where five patients had been treated across two dose cohorts by year-end 2025. Alongside these clinical advances, Perspective is expanding and upgrading its manufacturing footprint to support growing clinical demand, and it planned to outline these developments and its strategic trajectory to investors at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
The most recent analyst rating on (CATX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
On January 9, 2026, Perspective Therapeutics reported updated interim data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors, based on a December 10, 2025 data cut-off and presented at the 2026 ASCO Gastrointestinal Cancers Symposium. The update showed that among 56 patients across three dose cohorts there were no dose-limiting toxicities, treatment-related discontinuations, serious renal complications, or Grade 5 events, while Grade 3 or higher treatment-emergent adverse events occurred in 37.5% of patients and serious adverse events were not attributed to the study drug. Efficacy data from both patients in Cohort 1 and 23 patients in Cohort 2 indicated that 76% of these 25 patients were alive without disease progression after roughly 13 additional weeks of follow-up versus the prior readout, with a 39% objective response rate in Cohort 2 and evidence of deepening tumor responses over time. Investigators and company executives highlighted the combination of durable anti-tumor activity and favorable tolerability at the 5.0 mCi dose, the completion of dose-limiting toxicity assessment at the higher 6.0 mCi dose, and the expanding clinical dataset as factors that strengthen the program’s profile and underpin ongoing dose optimization and future registrational planning, signaling growing clinical momentum for the company’s lead radiopharmaceutical asset and broader platform.
The most recent analyst rating on (CATX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.